
Home » Immunomedics’ Trodelvy Shows Promise in Bladder Cancer and Breast Cancer Trials
Immunomedics’ Trodelvy Shows Promise in Bladder Cancer and Breast Cancer Trials
Immunomedics has released results from two clinical trials of its cancer drug Trodelvy (sacituzumab govitecan-hziy) in which the drug showed more promise in breast cancer and bladder cancer.
In a phase 3 study of the drug in metastatic triple-negative breast cancer, Trodelvy reduced the risk of death by 52 percent and had an overall survival rate of 12.1 months compared to 6.7 months with chemotherapy.
A separate phase 2 study evaluating the drug in heavily pretreated patients with metastatic urothelial cancer found that Trodelvy achieved a 27 percent overall response rate and a 5.9-month median duration of response.
Gilead Sciences is acquiring Trodelvy as part of its $21 billion acquisition of Immunomedics.
Upcoming Events
-
11Oct
-
16Oct
-
26Oct
-
02Nov
-
08Nov